8-K 1 v188421_8k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.  20549
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):  June 15, 2010
 
AMERICAN BIO MEDICA CORPORATION
 
(Exact name of registrant as specified in its charter)
 
New York
  
0-28666
  
14-1702188
(State or other jurisdiction of
incorporation)
  
(Commission File Number)
  
(IRS Employer Identification
Number)

122 Smith Road, Kinderhook, NY
12106
(Address of principal executive offices)
(Zip Code)
 
Registrant’s telephone number, including area code:  518-758-8158
 
Not applicable
(Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 

Item 5.07  Submission of Matters to a Vote of Security Holders
 
At the Annual Meeting of the Shareholders of American Bio Medica Corporation (the “Company”) held on June 15, 2010 (the “Annual Meeting”), at the Company’s corporate offices in Kinderhook, New York, the following matters were voted upon.
 
PROPOSAL NUMBER 1 – ELECTION OF DIRECTORS
 
Total Shares in
Attendance:
     12,010,758          
Outstanding Shares as of Record
Date (April 19, 2010)
       21,744,768  
                             
Director
  
For
    
Percent of
Votes
    
Withheld
    
Percent of
Votes
  
                             
Carl A. Florio
     11,566,505       96.3       444,253       3.7  
 
A description of the proposal can be found in the Company’s definitive proxy statement for the Annual Meeting filed with the U.S. Securities and Exchange Commission on April 28, 2010.
 
The nominee for election to the Board of Directors was elected for a three year term ending in 2013, or until his successor is elected and duly qualified. In addition to the director elected at the Annual Meeting, Edmund M. Jaskiewicz, Stan Cipkowski, Richard P. Koskey and Jean Neff continued their term of office after the Annual Meeting.
 
There were no other matters voted upon at the Annual Meeting, and there were no broker non-votes associated with this proposal.
 
 
 
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
AMERICAN BIO MEDICA CORPORATION (Registrant)
     
Dated: June 17, 2010
By:
/s/ Melissa A. Waterhouse
   
Melissa A. Waterhouse
   
Vice President & Chief Compliance Officer
   
Corporate Secretary